Alaunos CEO receives 7,761-share stock salary grant

Alaunos Therapeutics Chief Executive Officer Holger Weis reported a stock-based compensation transaction.

Accepted by SEC EDGAR 06/17/2026 - 04:47 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Alaunos Therapeutics Chief Executive Officer Holger Weis reported a stock-based compensation transaction. On June 12, 2026, he acquired 7,761 shares of Alaunos common stock at $2.26 per share as a grant categorized as a "grant, award, or other acquisition." A footnote explains these shares were issued in lieu of net salary, indicating they are compensation rather than an open‑market purchase. Following this award, Weis directly holds 12,672 common shares of Alaunos Therapeutics.

Insider Trade Summary

Grant/Award: 7,761 shares

Grant/Award 1 txn

Insider Weis Holger

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,761	$2.26	$18K

Holdings After Transaction: Common Stock — 12,672 shares (Direct)

Footnotes (1)

1. F1. Represents shares of common stock issued in lieu of net salary.

Key Figures

Shares granted: 7,761 shares Grant price per share: $2.26 per share Shares held after transaction: 12,672 shares +2 more

5 metrics

Shares granted 7,761 shares Common Stock grant on June 12, 2026

Grant price per share $2.26 per share Reported for the 7,761-share award

Shares held after transaction 12,672 shares Direct common stock holdings of CEO after grant

Number of acquire transactions 1 transaction Non-derivative grant coded as acquisition

Insider role Chief Executive Officer Position of reporting person Holger Weis

Key Terms

Grant, award, or other acquisition, in lieu of net salary, Common Stock, non-derivative

4 terms

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

in lieu of net salary financial

"Represents shares of common stock issued in lieu of net salary."

Common Stock financial

"security_title: "Common Stock" in the non-derivative transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

non-derivative financial

"transaction_type: "non-derivative" for the common stock grant"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Alaunos Therapeutics (TCRT) report for CEO Holger Weis?

Alaunos Therapeutics reported that CEO Holger Weis received 7,761 common shares as a stock award. The filing classifies it as a grant acquisition, rather than an open-market purchase, and notes the shares were issued in lieu of net salary as part of his compensation.

Was the Alaunos Therapeutics (TCRT) CEO Form 4 transaction an open-market stock purchase?

No, the Form 4 indicates the CEO’s 7,761 shares were issued as a grant in lieu of net salary. It is categorized as a "grant, award, or other acquisition," meaning compensation-related stock, not a discretionary open‑market buy of Alaunos shares.

How many Alaunos Therapeutics (TCRT) shares does CEO Holger Weis hold after this Form 4?

After the reported stock grant, CEO Holger Weis directly holds 12,672 Alaunos Therapeutics common shares. This total reflects his position immediately following the 7,761-share award issued as compensation, according to the Form 4 transaction details.

What price per share is reported in the Alaunos Therapeutics (TCRT) CEO grant?

The Form 4 reports a price of $2.26 per share for the 7,761 common shares granted to CEO Holger Weis. Although a price is listed, the filing describes this as a grant in lieu of net salary, not an open‑market trade at that price.

How is the Alaunos Therapeutics (TCRT) CEO stock award classified in the Form 4?

The transaction is coded "A" and described as a grant, award, or other acquisition. It is a non-derivative common stock award, with a footnote clarifying the 7,761 shares were issued in lieu of net salary, indicating routine equity compensation for the CEO.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weis Holger

(Last) (First) (Middle)

C/O ALAUNOS THERAPEUTICS, INC.

501 E. LAS OLAS BLVD. SUITE 300

(Street)

FORT LAUDERDALE FLORIDA 33301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alaunos Therapeutics, Inc. [ TCRT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/12/2026		A		7,761(1)	A	$2.26	12,672	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock issued in lieu of net salary.

	/s/ Weis, Holger	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)